Liver Fibrosis / Chronic Liver Disease (CLD)
Definition
Chronic liver disease (CLD) is the progressive damage and scarring of the liver parenchyma resulting from prolonged hepatic injury. It encompasses a continuum from early inflammation and fibrosis to cirrhosis (irreversible) and end-stage liver failure. CLD affects hundreds of millions worldwide and is a leading cause of liver transplantation and liver-related mortality.
Fibrosis staging — METAVIR system
The standard histological classification:
| METAVIR Stage | Description |
|---|---|
| F0 | No fibrosis |
| F1 | Portal fibrosis without septa |
| F2 | Portal fibrosis with few septa |
| F3 | Numerous septa without cirrhosis |
| F4 | Cirrhosis |
F4 (cirrhosis) sub-classification — Child-Pugh score:
| Class | Points | Prognosis | Clinical context |
|---|---|---|---|
| A | 5–6 | Compensated | Minimal complications |
| B | 7–9 | Decompensated | Significant functional impairment |
| C | 10–15 | End-stage | High mortality, transplant priority |
MELD score (Model for End-Stage Liver Disease): F4_B average ~15, F4_C average ~21 in the ALBOM cohort.
Major etiologies
- MASH (Metabolic-Associated Steatohepatitis / NAFLD) — most common in Western countries
- ALD (Alcohol-Related Liver Disease) — second most common
- Viral: HBV, HCV
- Autoimmune: AIH, PBC, PSC
- Metabolic: hemochromatosis, Wilson’s disease
- Other: cardiac hepatopathy, cryptogenic
Etiology distribution by fibrosis stage in ALBOM cohort (Table 1):
| Etiology | F0/F1 | F2 | F3 | F4_A | F4_B | F4_C | Total |
|---|---|---|---|---|---|---|---|
| MASH | 13 | 13 | 22 | 12 | 3 | 0 | 62 (36%) |
| ALD | 1 | 0 | 0 | 9 | 16 | 14 | 40 (23%) |
| HBV | 10 | 1 | 2 | 2 | 0 | 0 | 15 (9%) |
| HCV | 2 | 3 | 1 | 5 | 0 | 0 | 11 (6%) |
| AIH | 3 | 2 | 4 | 1 | 0 | 1 | 11 (6%) |
| ALD+MASH | 0 | 0 | 0 | 2 | 5 | 4 | 11 (6%) |
⚠️ Stage–etiology confound: MASH dominates early/intermediate stages; ALD + ALD+MASH dominates decompensated cirrhosis (F4_B/C ~85–90% alcohol-related). Etiology-stratified isoform analysis is a key unmet need.
Pathophysiology
- Chronic hepatocyte injury (necrosis, apoptosis) from toxins, metabolites, immune attack
- Activation of hepatic stellate cells → myofibroblasts → collagen deposition → fibrosis
- Portal hypertension → ascites, variceal bleeding, hepatic encephalopathy
- Reduced hepatic synthetic function → ↓ albumin, ↓ coagulation factors, ↓ bilirubin clearance
- Systemic oxidative stress and inflammation → modification of plasma proteins (including HSA)
- Progressive impairment of HSA’s non-oncotic functions (drug transport, antioxidant defense, immune modulation)
Current diagnostic markers
Gold standard
Liver biopsy (METAVIR histological staging) — invasive, 1–2% complication rate, sampling error (~30% misclassification for intermediate stages), not repeatable
Non-invasive tools in clinical use
| Method | Type | Measures | Limitation |
|---|---|---|---|
| FibroScan (transient elastography) | Imaging | Liver stiffness (kPa) | Confounded by inflammation, BMI, ascites |
| Splenic elastometry | Imaging | Splenic stiffness | Emerging, less validated |
| FIB-4 index = (age × AST) / (platelets × √ALT) | Score | Composite formula | Gray zone 1.30–2.67: indeterminate in ~30–40% of patients |
| FibroTest | Panel | 5 biochemical markers | Proprietary; moderate accuracy F2/F3 |
| FibroMeter | Panel | Multiple markers | Better than FIB-4 but still limited |
| Serum albumin | Single marker | Hepatic synthetic function | Only abnormal in advanced disease |
FIB-4 limitations in ALBOM cohort: overall accuracy 59.3% (3-class triage); 37.5% of gray-zone patients misclassified.
Classical marker performance by stage (from ALBOM supplemental data)
| Marker | Controls | F0/F1 | F2 | F3 | F4_A | F4_B | F4_C | Notes |
|---|---|---|---|---|---|---|---|---|
| Routine albumin (g/L) | 45 | 47.5 | 44.6 | 42.7 | 40.7 | 29.9 | 26.4 | Significant drop only in F4 (all sub-classes) |
| FIB-4 | Low | Low | ↑ | ↑ | ↑↑ | ↑↑↑↑ | ↑↑↑↑ | Stepwise; most significant F4_B/C vs earlier |
| AST (U/L) | Low | Low | Low | Low | ↑↑↑ | ↑↑↑ | ↑↑↑ | Not discriminatory in early fibrosis |
| Bilirubin (µmol/L) | Low | Low | Low | Low | Low | ↑↑↑↑ | ↑↑↑↑↑ | Late marker — only decompensated |
| ALT | — | — | — | — | — | — | — | No discriminatory power at any stage |
Staging method availability by stage (Table 2, ALBOM cohort)
| Stage | FibroScan used | Liver biopsy used | Both |
|---|---|---|---|
| F0/F1 | 35/36 (97%) | 4/36 (11%) | 3 (8%) |
| F2 | 23/23 (100%) | 5/23 (22%) | 5 (22%) |
| F3 | 28/30 (93%) | 12/30 (40%) | 10 (33%) |
| F4_A | 25/37 (68%) | 5/37 (13%) | 2 (5%) |
| F4_B | 3/26 (11%) | 6/26 (23%) | 1 (4%) |
| F4_C | 4/20 (20%) | 8/20 (40%) | 1 (5%) |
⚠️ FibroScan is essentially unavailable for decompensated patients (ascites impairs probe placement, liver stiffness confounded by congestion) — the very patients who most urgently need staging. This makes blood-based biomarkers critical at F4_B/C.
MELD scores (ALBOM cohort)
| Child-Pugh class | Average MELD |
|---|---|
| F4_A | 8 |
| F4_B | 15 |
| F4_C | 21 |
PTM-based biomarker candidates
Established in our research (ALBOM, el-balkhi-2025)
| Protein | PTM / Isoform | Method | Performance |
|---|---|---|---|
| HSA | Native HSA | Top-down LC-HR-MS | AUC 0.99 for F4_B vs controls |
| HSA | HSA+GLYC/Native ratio | Top-down LC-HR-MS | Sens 85%, Spec 100% for F4_B |
| HSA | HSA+CYS/Native ratio | Top-down LC-HR-MS | Sens 65%, Spec 99% for F4_C |
| HSA | Full spectral profile (OrdinalForest) | Top-down LC-HR-MS + ML | QWK 0.862–0.916; 81.5% accuracy vs 59.3% FIB-4 |
| HSA | HSA+CYS+2GLYC | Top-down LC-HR-MS | Monotonically increasing end-stage marker |
Other candidates in literature
| Protein | PTM | Notes |
|---|---|---|
| Transferrin | N-glycosylation changes | CDT (carbohydrate-deficient transferrin) used for ALD |
| HSA (functional) | Reduced binding capacity | NMR-based effective albumin assay |
| HSA | Homodimerization | Marker of oxidative stress, associated with cirrhosis prognosis |
| HSA | Conformational change | SMFA (spin-mediated fluorescence assay) in some centers |
Molecular rationale for HSA as CLD biomarker
- HSA is synthesized exclusively by the liver → quantity and quality directly reflect hepatocyte function
- Long half-life (~20 days) → accumulated PTMs integrate weeks of oxidative/metabolic stress
- Three isoform behavior patterns in CLD progression (decrease, biphasic, increase) encode complementary biological information
- The ratio approach (isoform/native) resolves the biphasic paradox and amplifies the diagnostic signal
- Paradigm shift: from anatomical staging (biopsy/elastography) to functional molecular staging via PTM fingerprint
Longitudinal follow-up
MALAHBAR study (NCT06318949) — underway. Multicentric longitudinal design to:
- Confirm ALBOM cross-sectional findings
- Establish predictive capacity (fibrosis progression, decompensation risk, HCC development)
- Test across broader etiology spectrum
Open questions for our research
- Etiology-specific isoform subprofiles (MASH vs ALD fingerprints)
- Predictive value: can isoform ratios predict who will decompensate?
- Can targeted LC-MRM-MS or immunoassay replace LC-HR-MS for clinical deployment?
- What are the pre-analytical stability requirements for isoform ratios in a multicenter setting?
Key studies in this vault
- el-balkhi-2025 — ALBOM manuscript: comprehensive cross-sectional staging study
- ALBOM study — project page with design, data, and pipeline details